McKesson Corporation vs Marathon Petroleum Corp — how do they compare? McKesson Corporation trades at $921.5 (market cap $106.14B), while Marathon Petroleum Corp trades at $460.2 (market cap $124.20B). The key difference: Marathon Petroleum Corp is the larger of the two by market cap, and Marathon Petroleum Corp pays the higher dividend (0.9%). Which is the better fit depends on your goals — on Pluang, investors hold McKesson Corporation for 74 Days and Marathon Petroleum Corp for 54 Days on average.
| MCK | MPC | |
|---|---|---|
Market Cap | $106.14B | $124.20B |
Volume | 794,405 | 1,923,373 |
Sector | Health | Energy |
52-Week High | $995.69 | $463.34 |
52-Week Low | $725.17 | $162.63 |
Typical Hold Time | 74 Days | 54 Days |
Enterprise Value | $112.67B | $150.72B |
Dividend Yield | 0.41% | 0.9% |
Signals from Pluang's Aura AI — not financial advice
McKesson (MCK) trades at $930.25, up 0.93% with strong bullish momentum after recent earnings beats and positive news flow. The stock shows robust technical strength with moving averages signaling bullish alignment and price trading near resistance at $926. Fundamentally, revenue growth accelerated to $359.1 billion in 2025 with consistent profitability, though thin margins remain a characteristic of the distribution business model. Recent catalyst includes the CVS Health partnership extension through 2032, reinforcing long-term revenue visibility.
Outlook remains positive with 81% analyst buy ratings and $956.43 consensus target suggesting 2.8% upside. Key opportunities include oncology/GLP-1 growth drivers and operational efficiency gains, while risks center on drug pricing pressure, policy uncertainty, and competitive threats. The company's improved cash flow generation and debt reduction support financial stability amid sector headwinds.
Marathon Petroleum (MPC) trades at $463.34, up 7.17% over 24 hours and near its 52-week high. The stock exhibits strong bullish momentum with consistent earnings beats and robust profitability metrics, including a 47.9% ROE. Recent news highlights refining margin strength amid tight global capacity, though potential diesel export curbs pose a risk. Technical indicators show bullish moving averages but an overbought RSI, with key resistance at $452.
MPC presents a compelling investment case with solid fundamentals, high analyst buy ratings (75.76%), and a consensus price target of $420.30. Upside is driven by elevated refining margins and earnings growth, but risks include regulatory threats to exports and volatile energy markets. The stock's current premium to target suggests cautious optimism amid near-term overbought conditions.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
McKesson is a leading wholesaler of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospitals networks, and healthcare providers. Along with AmerisourceBergen and Cardinal Health, the three account for well over 90% of the U.S. pharmaceutical wholesale industry. McKesson is currently divesting from its pharmaceutical wholesale and distribution in Europe and Canada in order to redeploy capital to strategic growth areas in the U.S. (oncology network and ecosystem, and biopharma services). Additionally, the company supplies medical-surgical products and equipment to healthcare facilities and provides a variety of technology solutions for pharmacies.
Read more on MCK →Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →